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Abstract
Purpose Complete interferon-γ receptor 1 (IFN-γR1) defi-
ciency is a primary immunodeficiency causing predisposition
to severe infection due to intracellular pathogens. Only 36
cases have been reported worldwide. The purpose of this ar-
ticle is to describe a large novel deletion found in 3 related
cases, which resulted in the complete removal of the IFNGR1
gene.
Methods Whole blood from three patients was stimulated
with lipopolysaccharide (LPS) and IFN-γ to determine pro-
duction of tumor necrosis factor (TNF), interleukin-12 p40
(IL-12p40) and IL-10. Expression of IFN-γR1 on the cell
membrane of patients’ monocytes was assessed using flow
cytometry. IFNGR1 transcript was analyzed in RNA and the
gene and adjacent regions were analyzed in DNA. Finally,
IL22RA2 transcript levels were analyzed in whole blood cells
and dendritic cells.
Results There was no expression of the IFN-γR1 on the
monocytes. Consistent with this finding, there was no IFN-γ
response in the whole blood assay as measured by effect on
LPS-induced IL-12p40, TNF and IL-10 production. A
119.227 nt homozygous deletion on chromosome 6q23.3
was identified, removing the IFNGR1 gene completely and
ending 117 nt upstream of the transcription start of the
IL22RA2 gene. Transcript levels of IL22RA2 were similar in
patient and control.
Conclusions We identified the first large genomic deletion of
IFNGR1 causing complete IFN-γR1 deficiency. Despite the
deletion ending very close to the IL22RA2 gene, it does not
appear to affect IL22RA2 transcription and, therefore, may not
have any additional clinical consequence.
Keywords MSMD . IFN-γR1 deficiency . IFNGR1 .
Mycobacterium fortuitum . EBV . IL22RA2
Introduction
Complete interferon-γ receptor 1 (IFN-γR1) deficiency is an
autosomal recessively inherited immunodeficiency, character-
ized by predisposition to infections with intracellular patho-
gens, in particular mycobacteria. This rare genetic defect dis-
rupts the interferon-γ (IFN-γ) pathway, leading to one of the
19 genetic etiologies of Mendelian Susceptibility to
Mycobacterial Diseases (MSMD) [1–3]. Complete
IFN-γR1and complete IFN-γR2 deficiency, represent the
most severe phenotypes of MSMD, whereas partial
IFN-γR1 deficiency is associated with a later onset and milder
disease course.
Most commonly, patients with complete IFN-γR1 defi-
ciency present with lymphadenopathy, hepatosplenomegaly
and intermittent fever in early childhood, caused by infection
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with weakly virulent, mostly environmental mycobacteria
such as Mycobacterium avium or the vaccine strain
Mycobacterium bovis bacillus Calmette-Guérin (BCG) [2].
Furthermore, patients with a complete defect appear to be
prone to develop malignancies [4–6]. Hematopoietic stem cell
transplantation (HSCT) is required to restore normal immune
function. Unfortunately graft failure rates are high [7, 8] and
consequently, the overall prognosis of patients with complete
IFN-γR1 deficiency remains poor.
The IFN-γR1 gene (IFNGR1) is located on chromosome
6q23.3 and stretches over 22 kb. Twenty-seven unique muta-
tions causing complete IFN-γR1 deficiency have been identi-
fied so far. These are all small variations, with the largest
deletion being only 22 nucleotides long (see Table 1). This
is the first description of a large genomic deletion, removing
IFNGR1 entirely and causing complete IFN-γR1 deficiency
in three related patients.
Case Reports
A 1-year-old girl (patient 1) of Turkish origin was seen in the
outpatient department with unilateral cervical lymphadenitis,
existing for 1 month despite treatment with flucloxacillin by
her family doctor. Apart from a persisting rhinitis the child had
no other complaints, especially no fever, night sweats, weight
loss, orthopnea or signs of hemorrhagic diathesis. There was
no history of animal contact or visits to foreign countries. Her
medical history included two episodes of respiratory tract in-
fections at the age of 6 and 7 months, requiring admission to
the hospital. Oxygen therapy, oral macrolide antibiotics and
bronchodilators were given. Chest X-rays showed bilateral
consolidations during the first admission, whichwere resolved
a month later. Beclomethasone inhalation therapy was started
after discharge. She was vaccinated according to the Dutch
national program, which does not include BCG vaccine.
Parents were consanguineous (Fig. 1a), but otherwise the fam-
ily medical history was unremarkable.
Physical examination revealed multiple small cervical
lymph nodes and one enlarged left pre-sternocleidomastoid
node (4×2 cm) without fluctuation or redness of the overlying
skin. Laboratory analysis revealed a leukocytosis with in-
creased granulocyte and lymphocyte numbers without leuke-
mic blasts, a mild anemia and a normal thrombocyte count.
Chest X-ray was normal. Serologic tests for streptococcus,
Bartonella sp., toxoplasmosis, Epstein-Barr virus and cyto-
megalovirus were negative. A bacterial infection was
suspected and amoxicillin/clavulanic acid was administered.
In light of progressive enlargement of the cervical lymph
node (4×6 cm) and appearance of supraclavicular nodes in
the next weeks, other diagnoses, such as malignancy and
(atypical) mycobacterial infection were considered.
Screening for anti-nuclear antibodies, sarcoidosis, human
immunodeficiency virus, germ cell tumor and neuroblastoma
was negative. Ultrasound did not show abscess formation or
intra-abdominal lymphadenopathy. Quantitative immuno-
globulin levels revealedmarginally raised IgM and IgA levels,
whereas IgG level was normal. Peripheral blood T-
lymphocyte counts were performed and showed increased
CD3 and CD4 counts and CD4 effector-memory population,
whereas the naïve T-cells were mildly decreased. The tuber-
culin skin test showed an induration of 7.0 mm. The result of
the IFN-γ release assay (QuantiFERON®) showed high
values for the specific mycobacterial antigens, however, the
assay was interpreted as invalid because of very high IFN-γ
values obtained for the negative control (64 IU/ml, normal
<0.35 IU/ml). The high IFN-γ in the negative control can
however be indicative of a complete IFN-γR defect. Fine
needle aspiration of the cervical lymph node showed non-
specific inflammation. Hence, bone marrow aspiration and
lymph node excision were performed. Apart from non-
specific reactive inflammation of the lymph node, no histo-
logic abnormalities, especially no granuloma formation orma-
lignancy, were noted. Bone marrow examinations revealed
reactive changes only with no evidence of malignant infiltra-
tion. After 2 weeks lymph node cultures became positive for
Mycobacterium fortuitum. Treatment was started with cipro-
floxacin and co-trimoxazole, eventually resulting in almost
complete normalization of all laboratory parameters. The neg-
ative control in the QuantiFERON® test decreased to 2.6 IU/
ml (normal <0.35 IU/ml). Importantly, the clinical condition
of the patient gradually improved.
Several weeks later the 3.5-year-old and almost 2-year-old
female cousins (patient 2 and 3, respectively) presented with
bilateral cervical lymphadenitis, which had been evident for
almost 2 weeks. Accompanying symptoms were rhinitis, cer-
vical pain and low-grade fever, which resolved spontaneously.
Apart from one episode of bronchial hyper-reactivity (patient
2) and rotavirus infection (patient 3) their medical history was
unremarkable. No BCG vaccine had been administered. Their
parents were first cousins and from the same consanguineous
Turkish family (Fig. 1a).
Physical examination revealed hepatosplenomegaly and
bilateral enlarged lymph nodes (patient 2: mid-jugular left
side 3.0×1.5 cm and right side 3.5×3.0 cm; patient 3:
upper-jugular left side 3.0 × 2.0 cm and right side
2.0×1.0) without fluctuation or redness. Laboratory anal-
yses showed elevated inflammatory parameters (ESR, CRP
and leukocytosis) and anemia in patient 2. Peripheral
blood T-lymphocyte counts showed increased CD3 and
CD4 effector-memory population in patient 2 and an in-
creased CD8 effector-memory population in patient 3.
Plasma EBV DNA analysis and EBV serology indicated
primary EBV infection in both patients (i.e. patient 2: IgG
EBV-VCA and IgG EBV-EBNA positive; patient 3: EBV
PCR 300 copies/ml at admission becoming negative in
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association with seroconversion of IgM to IgG EBV-
VCA). QuantiFERON® test showed similar results with
high negative control values in the IFN-γ release assay
as in patient 1. Ultrasound analysis confirmed the presence
of hepatosplenomegaly, without intra-abdominal lymphade-
nopathy nor abscess formation of the cervical nodes.
Fine needle aspiration of the cervical lymph nodes showed
no mycobacterial infection or other abnormalities.
Patients 2 and 3 were closely monitored without prophy-
laxis for mycobacterial diseases. During this follow-up a skin
infection developed in patient 2 due to varicella zoster virus



































119,227 nt genomic deletion
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Fig. 1 Pedigree, immunological
assays and genetic analysis of
patients. Family tree of patients 1,
2 and 3 (a). In vitro TNF
production in response to
stimulation with LPS plus various
concentrations of IFN-γ in patient
1 and healthy control (b). Flow
cytometry showing absent cell
surface expression of IFN-γR1
(GIR-94 antibody, BD
Biosciences) on monocytes of
patient 2 (c). Large homozygous
deletion on chromosome 6q23.3
identified with PCR and
sequencing, removing the entire
IFN-γR1 gene (IFNGR1) and
surrounding region (d). Deletion
terminates 117 nt upstream of the
transcription start of IL22RA2
(not to scale). The first and last
nucleotides of the deletion are:
137,173,766 and 137,292,992
H. sapiens chromosome 6,
GRCh38.p2 Primary Assembly
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successfully treated with valaciclovir and flucloxacillin,
respectively. The treatment of patient 3 required two
days hospitalization for intravenous flucloxacillin.
Otherwise the clinical courses were unremarkable.
Although the size of the lymph nodes decreased over
time in both patients, the hepatosplenomegaly and in-
flammatory parameters were persistently elevated for
several months in the eldest (patient 2) in contrast to
her younger sister (patient 3), in whom spontaneous
resolution was observed over a period of 4 weeks.
Because of the persisting lymphadenopathy in patient
2, bone marrow aspiration and lymph node excision
were recently performed. Very similar to the observation
in patient 1, non-specific reactive inflammation of the
lymph node and no histologic abnormalities, especially
no granuloma formation or malignancy, were noted.
EBV in situ hybridization was negative, and no other
(mycobacterial) infection could be detected.
IFN-γ concentrations were determined in serum samples of
the patients by Luminex assay. These were on the day of their
first visit our clinic 2330, 1144 and 1568 pg/ml (normal 7–
124 pg/ml) in patient 1, 2 and 3, respectively. During follow-
up (after 6.5, 3.5 and 3.5 months) these IFN-γ concentrations




Whole blood assay and IFN-γR1 expression analysis were
performed as previously described [39, 40].
Genetic Analysis of IFNGR1
DNA and RNAwere isolated from whole blood; cDNAwas
synthesized from RNA with SuperScript III (Invitrogen,
Bleiswijk, the Netherlands). Reverse transcription polymerase
chain reaction (RT-PCR) of the IFNGR1 transcript from
cDNA was performed (primers and conditions available on
request). PCRs were performed to amplify all exons of
IFNGR1 from genomic DNA. Various primer sets were sub-
sequently designed to amplify the genomic region around
IFNGR1 and to determine the extent of the deletion. The
primers that were found to cover the deletion were
DEL307F 5′-AAAGCTTGGTTTCATGCTCTAA-3′ and
DEL307R 5′-GGGACGCCATGTTATGTTTT-3′. These are
located at 137293106–137293085 and 137173480–
137173499, respectively, on Homo sapiens chromosome 6,
GRCh38.-2 Primary Assembly.
Analysis of IL22RA2 Transcription by Dendritic Cells
and Whole Blood Cells
PBMCs isolated from whole blood were cultured in IMDM
(containing 10 % human serum, glutamine, penicillin, strep-
tomycin) allowing monocytes to adhere to the flask surface.
Non-adherent cells were washed away after 18 h. Monocytes
were cultured for 4 days with 20 ng/ml GM-CSF (Sanquin,
Amsterdam, NL) and 20 ng/ml IL-4 (Peprotech, London, UK)
to induce differentiation to dendritic cells and 100 nM retinoid
derivative AM580 (Sigma, St. Louis, MI, USA) to induce
IL22RA2 transcription. Cells were washed and cultured for
another 3 days in IMDM containing 10 % fetal calf serum,
glutamine, penicillin, streptomycin, GM-CSF, IL-4 and
AM580. RNA was isolated, cDNA was synthesized with
SuperScript III (Invitrogen) and qRT-PCR was performed to
detect TBP (reference gene) and IL22RA2 transcripts (primers
and conditions available on request). qRT-PCR was also per-
formed in RNA isolated from whole blood cells.
Results
No IFN-γ Response in patients’ Cells and no IFN-γR1
Expression on patients’ Monocytes
To determine whether the IFN-γ pathway was functional, we
stimulated whole blood of patient 1 with LPS and IFN-γ. TNF
productionwas low in response to LPS and not upregulated by
the addition of IFN-γ in various concentrations (Fig. 1b).
Furthermore, there was no upregulation of IL-12p40 or down-
regulation of IL-10 in response to the addition of IFN-γ (data
not shown). The patient is capable of producing cytokines in
the same whole blood assay, as illustrated by the IL-10 pro-
duction in response to LPS (Supplemental Figure 1). Results
of patients 2 and 3 were identical. Flow cytometry showed
that cell surface expression of IFN-γR1 on patients’ mono-
cytes was absent (Fig. 1c).
The Patients are Homozygous for a Large Deletion
Removing IFNGR1 Completely
Subsequent analysis of RNA of patient 1 showed that
IFNGR1 transcripts were absent and IFNGR1 exons could
not be amplified from genomic DNA of the patient. Using
various primer combinations in the regions flanking the
IFNGR1 gene, we were able to establish that a genomic dele-
tion of 119.227 nt was present (Fig. 1d). The first and last
nucleotides of the deletion are 137173766 and 137292992
(Homo sapiens chromosome 6, GRCh38.p2 Primary
Assembly) encompassing the entire IFNGR1 gene but leaving
the flanking genes LOC105378017 (uncharacterized gene)
and IL22RA2 (encoding a soluble IL-22 receptor, also known
200 J Clin Immunol (2016) 36:195–203
as IL-22BP) intact. The deletion was homozygously present in
all three patients and heterozygously in all four parents and
two of the three siblings of patient 1 (Fig. 1a).
Similar IL22RA2 Transcript Levels in Patient 2
and Control
Because the genomic deletion ended only 117 nt upstream of
the transcription start of IL22RA2 we hypothesized this dele-
tion could affect its transcription. Therefore, we analyzed
IL22RA2 transcripts by RT-PCR in RNA isolated from den-
dritic cells stimulated with the retinoid derivative AM580,
which is known to upregulate IL22RA2 transcription. In both
patient 2 and a control IL22RA2 transcript variant 2 (lacking
exon 4, containing exon 6) was the most abundant transcript,
while IL22RA2 transcript variant 1 (containing all exons) was
also present. IL22RA2 transcript variant 3 (lacking exon 4 and
6) was not detected in the samples. To determine whether the
promoter is not continuously active we assessed whether
IL22RA2 transcripts were detectable in whole blood cells. In
RNA isolated from whole blood cells IL22RA2 transcripts
were not detectable in samples from the three patients and a
control (data not shown). qRT-PCR for IL22RA2 showed that
the ratio between patient/control transcript levels is 1,92 in the
AM580-stimulated dendritic cells and confirmed that in whole
blood IL22RA2 transcripts are undetectable in the patient and
control.
Discussion
We describe three related patients with complete IFN-γR1
deficiency. They presented between 1 and 4 years of age with
persistent or marked cervical lymphadenopathy as the main
symptom. Lymph node tissue from patient 1 cultured
M. fortuitum as the causative pathogen and primary EBV in-
fection was found in patients 2 and 3.
To date, only 36 cases of complete IFN-γR1 deficiency
have been reported. These patients are summarized in
Table 1. All but one patient developed mycobacterial infec-
tion, including BCG post vaccination infections in fourteen
cases. In addition, other significant pathogens were identified
in approximately one third of the cases. The disease course of
these infections was either comparable (e.g. EBV) or more
severe (e.g. Salmonellae, Pseudomonas aeruginosa, Listeria
monocytogenes) than observed in immunocompetent subjects.
Furthermore, late-onset malignancy (pineal germinoma,
Kaposi sarcoma and two cases of B-cell lymphoma) following
diagnosis developed in four cases (Table 1: patients 32z, 21r,
12 k and 28v, respectively).
The clinical presentation of patient 1 is similar to previous-
ly reported cases. M. fortuitum has been identified in eight
previous cases, and is therefore a well-known pathogen
causing disease in patients with complete IFN-γR1 deficiency
(Table 1). Furthermore, the very high serum levels of IFN-γ as
detected in the negative control of the Quantiferon test and in
the Luminex assay are correlated with the lack of IFN-γR1
expression on the cell surface. This phenomenon has been
described before in patients with complete IFN-γR1 or
IFN-γR2 deficiency [41]. Patients 2 and 3 presented with
cervical lymphadenopathy and splenomegaly due to primary
EBV infection, which has not been reported before as a first
presentation in patients with complete IFN-γR1 deficiency.
The clinical disease course of the EBVinfection was relatively
unremarkable, but hepatosplenomegaly and inflammatory pa-
rameters (i.e. elevated ESR, CRP, leukocytosis, lymphocyto-
sis, and hypergammaglobulinemia) were more pronounced
compared to EBV infection in subjects with normal immune
function. In patient 2 these laboratory parameters remained
abnormal for over 4 months. When compared to the previous-
ly described cases this benign clinical phenotype is likely due
to lack of exposure thus far in these very young patients to
pathogenic mycobacteria.
Twenty-seven different mutations causing complete
IFN-γR1 deficiency have been reported (Leiden Open
Variation Database, www.lovd.nl/IFNGR1 and Table 1).
These mutations are single nucleotide variations, small
duplications, insertions or deletions. The largest reported
genomic deletion was only 22 nt long (patient 17n, Table 1).
Complete absence of IFNGR1 due to a large deletion has not
been reported previously. It remains unclear whether the size
of the deletion (119.227 nt) has additional clinical conse-
quences other than complete IFN-γR1 deficiency. No coding
regions besides IFNGR1 are known to be located in the area of
the deletion. However, the deletion terminates 117 nt upstream
of the transcription start of the IL22RA2 gene, raising suspi-
cion that binding of transcription-regulating factors might be
affected. Transcription of IL22RA2 leads to production of IL-
22 binding protein (IL-22BP), a soluble receptor, which is
capable of binding and inactivating IL-22 [42]. IL-22BP is
produced by dendritic cells [43]. We were able to detect
IL22RA2 transcription in response to retinoid stimulation of
the dendritic cells that was similar between patient and control
in both abundance and transcript variants present. Transcript
variant 2, encoding the IL-22BP isoform which efficiently
binds and inhibits IL-22 [42, 44], was the most abundant tran-
script detected. To determine whether the promoter is not con-
tinuously active we also assessedwhether IL22RA2 transcripts
were detectable in whole blood cells. This was neither the case
in patients nor in control RNA. Together these results suggest
that IL22RA2 transcription is not affected.
At time of publication, infectious parameters of patient 2
remain elevated several months after primary EBV infection,
while bacterial cultures of lymph node and blood are repeat-
edly negative. Patients 1 and 3 are in good clinical condition,
without signs of active infection. Hematopoietic stem cell
J Clin Immunol (2016) 36:195–203 201
donor searches are in progress in order to facilitate future
HSCT for all three children. Unfortunately, graft failure has
been reported in approximately one third of transplanted cases
(Table 1). This increased rate is most likely due to high plasma
concentrations of IFN-γ [41], which has anti-hematopoietic
activity [45]. Options for reducing plasma IFN-γ around
HSCT with anti-IFN-γ monoclonal antibodies are currently
being explored.
In conclusion, we report three related cases of complete
IFN-γR1 deficiency caused by a novel large genomic dele-
tion, removing IFNGR1 entirely and ending close to the
IL22RA2 gene. The disease course of the patients reported
here was relatively unremarkable and similar to previously
reported cases of complete IFN-γR1 deficiency, except for
primary EBV infection as the presenting infection in two of
three patients.
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